Literature DB >> 30667061

The role of elective neck dissection in patients with adenoid cystic carcinoma of the head and neck.

Roy Xiao1, Rosh K V Sethi2,3, Allen L Feng2,3, Joel B Fontanarosa3, Daniel G Deschler2,3,4.   

Abstract

OBJECTIVE: To investigate the frequency and outcomes of elective neck dissection (END) for adenoid cystic carcinoma (ACC) of the head and neck.
METHODS: The National Cancer Database was queried for a cohort study of patients with ACC of the major salivary glands, nasal cavity/nasopharynx, hard/soft palate, tongue, floor of mouth, larynx, and oral cavity who underwent primary surgical resection from 2004 to 2014. Multivariable logistic regression was used to identify predictors of END and occult nodal metastasis. Overall survival (OS) was estimated using the Kaplan-Meier method and modeled with Cox proportional hazards regression.
RESULTS: Among 2,807 patients with ACC treated surgically, 636 (22.7%) underwent END. Patients with ACC of the salivary glands and tongue most frequently underwent END; patients with hard/soft palate (odds ratio [OR] 0.06, P < 0.001) and nasal cavity/nasopharynx (OR 0.05, P < 0.001) ACC rarely underwent END compared to patients with major salivary gland cancer. Increasing tumor (T) stage (T4 vs. T1, OR 3.02, P < 0.001) was associated with END. Patients with advanced T3 to T4 ACC of the major salivary glands demonstrated extended OS associated with END (5-year OS 78.1% vs. 70.4%, P = 0.041) on Kaplan-Meier analysis and with END with adjuvant radiation therapy (hazard ratio 0.55, P = 0.027) using Cox proportional hazards regression. Elective neck dissection for T4 ACC of the salivary glands (21.3%) and tongue (25.5%) most consistently revealed occult nodal metastasis.
CONCLUSION: Elective neck dissection for ACC of the major salivary glands or tongue is most likely to reveal occult nodal metastasis. Elective neck dissection is associated with extended OS for advanced-stage ACC of the major salivary glands. LEVEL OF EVIDENCE: NA Laryngoscope, 129:2094-2104, 2019.
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Adenoid cystic carcinoma; National Cancer Database; elective neck dissection; major salivary gland; occult nodal metastasis; overall survival

Mesh:

Year:  2019        PMID: 30667061     DOI: 10.1002/lary.27814

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  The role of elective neck dissection in high-grade parotid malignancy: A hospital-based cohort study.

Authors:  R Alex Harbison; Alan J Gray; Ted Westling; Marco Carone; Cristina P Rodriguez; Neal D Futran; Richard B Cannon; Jeffrey Houlton
Journal:  Laryngoscope       Date:  2019-08-29       Impact factor: 3.325

2.  Elective neck dissection in adenoid cystic carcinoma of head and neck: yes or no? A systematic review.

Authors:  Ivica Luksic; Petar Suton
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-03       Impact factor: 2.503

Review 3.  Rare Diseases of the Orbit.

Authors:  Ulrich Kisser; Jens Heichel; Alexander Glien
Journal:  Laryngorhinootologie       Date:  2021-04-30       Impact factor: 1.057

Review 4.  Adenoid cystic carcinoma of the sublingual gland developing lung metastasis 20 years after primary treatment: A case report and literature review.

Authors:  Keiichi Ohta; Shinpei Matsuda; Akitoshi Okada; Masato Sasaki; Yoshiaki Imamura; Hitoshi Yoshimura
Journal:  Medicine (Baltimore)       Date:  2021-12-10       Impact factor: 1.817

Review 5.  Occult Neck Metastases in Head and Neck Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jacopo Zocchi; Matteo Campa; Giulia Bianchi; Oreste Iocca; Pasquale Di Maio; Gerardo Petruzzi; Silvia Moretto; Flaminia Campo; Armando De Virgilio; Vincent Vander Poorten; Raul Pellini
Journal:  J Clin Med       Date:  2022-08-22       Impact factor: 4.964

6.  Occult neck metastases risk factors and the role of elective neck dissection in cT3-4N0 adenoid cystic carcinoma of the parotid gland.

Authors:  Junhui Yuan; Fan Meng; Chunmiao Xu; Wenlu Li; Shuang Wu; Hailiang Li
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.